Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR-Reference-Cited by-同舟云学术

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR

Published:2011-01-10 Issue:2 Volume:53 Page:389-395
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Thompson Alexander J.,Santoro Rosanna,Piazzolla Valeria,Clark Paul J.,Naggie Susanna,Tillmann Hans L.,Patel Keyur,Muir Andrew J.,Shianna Kevin V.,Mottola Leonardo,Petruzzellis Daniela,Romano Mario,Sogari Fernando,Facciorusso Domenico,Goldstein David B.,McHutchison John G.,Mangia Alessandra

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.24068/fullpdf

Reference13 articles.

1. The global burden of hepatitis C;Lavanchy;Liver Int,2009

2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

4. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C;McHutchison;Gastroenterology,2002

5. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency;Sumi;Hum Genet,2002

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy;BMC Infectious Diseases;2024-03-11

2. WITHDRAWN: Analysis of host genetic variations associated with response to anti-HCV therapies in global populations;Meta Gene;2021-03

3. Relationships Between Vitamin D Status and Cytokine: Results from Interferon-Based Therapy in Non-Cirrhotic, Treatment-Naïve Patients with Chronic Hepatitis C Infection;Journal of Inflammation Research;2020-12

4. Pharmacogenetic variants associated with off-target adverse drug reactions are mostly predicted to be benign;2019-09-23

5. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression;Gastroenterology;2019-01